Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: A meta-analysis of seven randomized clinical trials

Journal of Thoracic Oncology

Volumn 2, Issue 10, 2007, Pages 939-946

  Douillard, Jean Yves ^a   Laporte, Silvy ^b   Fossella, Frank ^c   Georgoulias, Vassilis ^d   Pujol, Jean Louis ^e   Kubota, Kaoru ^f   Monnier, Alain ^g   Kudoh, Shinzoh ^h   Rubio, Jaime Ernesto ⁱ   Cucherat, Michel ^j  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY HOSPITAL OF IRAKLION   (Greece)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

^g Centre Hospitalier A Bouloche   (France)

^h OSAKA CITY GENERAL HOSPITAL   (Japan)

ⁱ Centro Medico National de Occ   (Mexico)

^j HOSPICES CIVILS DE LYON   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; VINDESINE;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HAZARD ASSESSMENT; HUMAN; INFORMATION RETRIEVAL; LUNG NON SMALL CELL CANCER; MEDICAL INFORMATION; MEDICAL LITERATURE; MEDLINE; META ANALYSIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PUBLICATION; SENSITIVITY ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL RATE; TAXOIDS; VINBLASTINE; VINDESINE;

EID: 34848818029     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318153fa2b     Document Type: Article

References (46)

1. Parkin DM, Bray FJ, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: Early-stage disease. Oncology (Williston Park) 2003;17:357-364.
3. Abratt RP, Hart GJ. 10-year update on chemotherapy for non-small cell lung cancer. Ann Oncol 2006;17(Suppl 5):v33-v36.
4. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
5. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52. randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899-909.
6. Hotta K, Matsuo K, Ueoka H, et al. Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 2004;15:1782-1789.
7. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-367.
8. Kelly K, Crowley J, Bunn PA Jr, et al. Treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218.
9. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
10. Comella P, Frasci G, Panza N, et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 2000;18:1451-1457.
11. Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 1981;95:414-420.
12. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1998;16:2459-2465.
13. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
14. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
15. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22:254-261.
16. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-3663.
17. Le Chevalier T, Scagliotti G, Natale R, et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 2005;47:69-80.
18. Sylvester R, Collette L, Duchateau L. The role of meta-analyses in assessing cancer treatments. Eur J Cancer 2000;36:1351-1358.
19. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997;315:1533-1537.
20. Michiels S, Piedbois P, Burdett S, et al. Meta-analysis when only the median survival times are known: a comparison with individual patient data results. Int J Technol Assess Health Care 2005;21:119-125.
21. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
22. Parmar M, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815-2834.
23. Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in metaanalysis. In: M Egger (Ed.). Systematic Reviews in Health Care. Metaanalysis in Context. London: BMJ Books, 2001.
24. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000;53:1119-1129.
25. EasyMA.net; available at http://www.spc.univ-lyon1.fr/easyma.net (accessed March 5, 2007).
26. Douillard JY, Gervais R, Dabouis G, et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by crossover to single-agent docetaxel or vinorelbine at progression: final results of a randomized phase II study. Ann Oncol 2005;16:81-89.
27. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005;23:2937-2945.
28. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005;16:602-610.
29. Monnier A, Zatloukal P, Siffnerova H, et al. Docetaxel (D) versus vinorelbine-cisplatin (VC) as front-line treatment for patients with advanced non-small cell lung cancer (NSCLC) and with a normal level of serum alpha 1 acid glycoprotein (AAG): additional data on quality of life (QOL). Preliminary results. Proc Am Soc Clin Oncol 2003; abstract 2680.
30. Rubio JE, Sahagun G. A randomised phase III trial comparing docetaxel + carboplatin (DCP) vs vinorelbine + carboplatin (VCP) in non small cell lung cancer (NSCLC) stage III and IV. Proc Am Soc Clin Oncol 2003;abstract 2827.
31. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018.
32. Proceedings of the European Consensus Conference on Medical Treatment of Non-Small Cell Lung Cancer. Lung Cancer 2002;38(Suppl 3):S1-S85.
33. Stewart LA, Parmar MK. Meta-analysis of the literature or of individual patient data: is there a difference? Lancet 1993;341:418-422.
34. Piedbois P, Buyse M. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol 2004;22:3839-3841.
35. Pujol JL, Barlesi F, Daures JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer 2006;51:335-345.
36. Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: a meta-analysis of response, toxicity, and survival. Cancer 1998;82:116-126.
37. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer. A meta-analysis. Cancer 1995;76:593-601.
38. PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998;352:257-263.
39. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996;125:723-729.
40. Auperin A, Le Pechoux C, Pignon JP, et al. Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients. Ann Oncol 2006;17:473-483.
41. D'Addario G, Pintilie M, Leighl NB, et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005;23:2926-2936.
42. Sakamoto J, Teramukai S, Watanabe Y, et al. Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected nonsmall-cell lung cancer. J Immunother 2001;24:250-256.
43. Souquet PJ, Chauvin F, Boissel JP, et al. Meta-analysis of randomised trials of systemic chemotherapy versus supportive treatment in non-resectable non-small cell lung cancer. Lung Cancer 1995;12(Suppl 1):S147-S154.
44. Perol M, Perol D. The role of meta-analysis in assessing the treatment of advanced non-small cell lung cancer. Rev Pneumol Clin 2004;60:29-37.
45. Agelaki S, Androulakis N, Agelidou A, et al. Phase III randomized study of oarl vinorelbine (oV) and gemcitabine (G) (oVG) versus docetaxel (D) and gemcitabine (DG) as first-line treatment of patients with advanced non-small cell lung cancer (NSCLC): a preliminary report. Proc Am Soc Clin Oncol 2007; abstract 7538.
46. Karampeazis A, Vamvakas L, Agelidou A, et al. Docetaxel compared with vinorelbine in elderly patients with advanced non-small cell lung cancer (NSCLC): a randomized phase Hellenic Oncology Research Group trial. Proc Am Soc Clin Oncol 2007; abstract 7615.